<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">UNITED
STATES</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white">PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white">Date
of Report (Date of earliest event reported) 28 October 2012</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><img src="tlogo1.jpg"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>AMARANTUS
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">Commission
File No.&nbsp;&nbsp;<B><U>333-148922</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 50%; font-weight: bold; text-align: center"><B>26-0690857</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</TD>
    <TD STYLE="text-align: center">&nbsp;(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">incorporation or organization)</TD>
    <TD STYLE="text-align: center">identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">675 Almanor Ave., Sunnyvale, CA</TD>
    <TD STYLE="font-weight: bold; text-align: center">94085</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address&nbsp;of&nbsp;principal&nbsp;executive&nbsp;offices)</TD>
    <TD STYLE="text-align: center">(zip&nbsp;code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(408) 737-2734</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instructions
A-2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prepared By:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><img src="tlogo2.jpg"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>JSBarkats,</I></B> PLLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">18 East 41<SUP>st</SUP> Street, 19<SUP>th</SUP>
Fl.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.JSBarkats.Com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This
Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented
by Amarantus&rsquo; PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of
Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions,
including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks,
uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under
&quot;Risk Factors&quot; in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in
other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these
forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in
its views or events or circumstances that occur after the date of this presentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Item 8.01. Other Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On
28 October 2012 Amarantus BioSciences, Inc. released the results of an Independent Academic Study report demonstrating that MANF
(mesencephalic astrocyte-derived neurotrophic factor), the Company&rsquo;s leading drug candidate for treatment for Parkinson&rsquo;s
disease, when administered in the substantia nigra zona compacta (SNc) in the ventral midbrain, reduced the neurological deficits
associated with Parkinson&rsquo; disease. The accepted cause of Parkinson&rsquo;s disease is the death of 70-80% of the dopaminergic
(DAergic) neurons in the SNc in the ventral midbrain. Previous animal model studies directed to Parkinson&rsquo;s disease have
shown that protecting DAergic cell bodies in the SNc without increasing DAergic reinnervation in the striatum does not correct
the neurological deficits association with Parkinson&rsquo;s disease. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Recent
clinical trials of GDNF (glial cell line-derived neurotrophic factor), the model drug developed in the treatment of Parkinson&rsquo;s
disease, indicates that while GDNF protects DAergic cell bodies in the SNc, it does not correct neurological deficits, which is
necessary for a functional recovery in Parkinson&rsquo;s disease. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
Independent Study indicates that MANF, the Company&rsquo;s leading drug candidate, significantly reduces neurological deficits
in a Parkinson&rsquo;s Disease model, while GDNF does not; thus, providing a firm basis for the continue investment in MANF development.
The next step in MANF development is clinical studies utilizing a primate model. If those studies are positive, they will be incorporated
in the toxicological data of an investigational new drug application package to the FDA to be submitted prior to starting a Phase
I/II clinical trial for MANF in the treatment of Parkinson&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">A copy of the Independent
MANF study is attached as Exhibit 99.1 to this Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Item 9.01 Financial
Statements and Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.5pt; text-indent: -67.5pt"><FONT STYLE="background-color: white"><B>(d)
Exhibits. </B>The following Exhibit is furnished solely for purposes of Item 8.01 of this Form 8-K:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-weight: bold; text-align: center">Exhibit</TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 88%; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">No.</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">99.1</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>Report: MANF, Delivered to the Substantia Nigra, Corrects Neurological Deficits in the Rodent Model of Parkinson&rsquo;s Disease</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated: 01 November 2012.</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Amarantus BioSciences, Inc. (Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 46%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: justify; text-indent: 12pt">/s/ Gerald Commissiong</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 12pt">Gerald Commissiong</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 12pt">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v327259_8k.htm", "description": "8-K", "secsgml_size_bytes": 18688}]
{"company-data": {"conformed-name": "Amarantus BioSciences, Inc.", "cik": "0001424812", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-148922", "film-number": "121175010"}, "business-address": {"street1": "675 ALMANOR AVE.", "city": "SUNNYVALE", "state": "CA", "zip": "94085", "phone": "(408) 737-2734"}, "mail-address": {"street1": "675 ALMANOR AVE.", "city": "SUNNYVALE", "state": "CA", "zip": "94085"}, "former-company": {"former-conformed-name": "Jumpkicks, Inc.", "date-changed": "20080123"}}
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported) 28 October 2012
AMARANTUS
BIOSCIENCES, INC.
(Exact name of registrant as specified in
its charter)
Commission
File No.
333-148922
Delaware
26-0690857
(State or other jurisdiction of
(IRS Employer
incorporation or organization)
identification No.)
675 Almanor Ave., Sunnyvale, CA
94085
(Address of principal executive offices)
(zip code)
(408) 737-2734
(Registrant's
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instructions
A-2 below):
¨
Written
communications pursuant to Rule 425 under the Securities Act.
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act.
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
Prepared By:
JSBarkats,
PLLC
18 East 41
st
Street, 19
th
Fl.
New York, NY 10017
www.JSBarkats.Com
This
Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented
by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of
Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions,
including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks,
uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under
"Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in
other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these
forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in
its views or events or circumstances that occur after the date of this presentation.
Item 8.01. Other Events
On
28 October 2012 Amarantus BioSciences, Inc. released the results of an Independent Academic Study report demonstrating that MANF
(mesencephalic astrocyte-derived neurotrophic factor), the Company's leading drug candidate for treatment for Parkinson's
disease, when administered in the substantia nigra zona compacta (SNc) in the ventral midbrain, reduced the neurological deficits
associated with Parkinson' disease. The accepted cause of Parkinson's disease is the death of 70-80% of the dopaminergic
(DAergic) neurons in the SNc in the ventral midbrain. Previous animal model studies directed to Parkinson's disease have
shown that protecting DAergic cell bodies in the SNc without increasing DAergic reinnervation in the striatum does not correct
the neurological deficits association with Parkinson's disease.
Recent
clinical trials of GDNF (glial cell line-derived neurotrophic factor), the model drug developed in the treatment of Parkinson's
disease, indicates that while GDNF protects DAergic cell bodies in the SNc, it does not correct neurological deficits, which is
necessary for a functional recovery in Parkinson's disease.
The
Independent Study indicates that MANF, the Company's leading drug candidate, significantly reduces neurological deficits
in a Parkinson's Disease model, while GDNF does not; thus, providing a firm basis for the continue investment in MANF development.
The next step in MANF development is clinical studies utilizing a primate model. If those studies are positive, they will be incorporated
in the toxicological data of an investigational new drug application package to the FDA to be submitted prior to starting a Phase
I/II clinical trial for MANF in the treatment of Parkinson's disease.
A copy of the Independent
MANF study is attached as Exhibit 99.1 to this Report.
Item 9.01 Financial
Statements and Exhibits
(d)
Exhibits.
The following Exhibit is furnished solely for purposes of Item 8.01 of this Form 8-K:
Exhibit
No.
Description
99.1
Report: MANF, Delivered to the Substantia Nigra, Corrects Neurological Deficits in the Rodent Model of Parkinson's Disease
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: 01 November 2012.
Amarantus BioSciences, Inc. (Registrant)
By:
/s/ Gerald Commissiong
Gerald Commissiong
Chief Executive Officer